You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
The unfortunate appearance of AIDS, the manifold problems with herpesviruses and other viruses attacking humans have led to an enormous dynamism of worldwide research and to an immense increase in the corresponding literature. With this first Special Topic of the monograph series Progress in Drug Research, the editor and the publishers undertake an effort to supply concise reviews on virus research, especially on the development of new and future antiviral agents in some important and widespread viral diseases. Latest Progress in Drug Research articles dealing with new chemotherapeutics for the treatment of the most threatening viral diseases are presented. These very well received articles were upgraded and supplemented with new chapters to form this actual overview of the achievements in the respective fields of virus research. This special volume contains six review articles covering the latest studies on the HIV and hepatitis C and B viruses...
Hepatitis C virus (HCV) was first identified in 1989 as the etiologic agent of non-A, non-B hepatitis [1] and is currently recognized as the leading cause of chronic liver disease worldwide. In contrast to hepatitis B virus infection, in which only about 5% of adult infections become chronic, more than 80% of HCV-infected patients develop chronic hepatitis. Moreover, 20-50% of those persistently infected with HCV will develop liver cirrhosis and hepatocellu lar carcinoma (HCC) [2]. It is estimated that there are 10,000 deaths in the USA per year due to chronic liver failure or HCC [3]. In addition, HCV dis 25-50% of all liver transplants in US centers, and the ease is responsible for recurrence of HCV infection following liver transplantation is universal [4]. Typically, HCV disease emerges after a 10-20 year period during which symp toms, if they exist at all, are mild and non-specific. Although the prevalence varies greatly among different countries, it has been estimated that up to 170 million people (3% of the world's population), are infected with HCV [5]. A recent study in the USA found that 65% of all HCV-infected persons are 30 to 49 years old [6].
Founded in 1959 by its current Editor, the series has moved from its initial focus on medicinal chemistry to a much wider scope. Today it encompasses all fields concerned with the development of new therapeutic drugs and the elucidation of their mechanisms of action, reflecting the increasingly complex nature of modern drug research. Invited authors present their biological, chemical, biochemical, physiological, immunological, pharmaceutical, toxicological, pharmacological and clinical expertise in carefully written reviews and provide the newcomer and the specialist alike with an up-to-date comprehensive list of prime references. Each volume of Progress in Drug Research contains fully cross-referencing indices which link the books together, forming a virtually encyclopaedic work. The series thus serves as an important, time-saving source of information for researchers concerned with drug research and all those who need to keep abreast of the many recent developments in the quest for new and better medicines.
Progress in Drug Research is a prestigious book series which provides extensive expert-written reviews on a wide spectrum of highly topical areas in current pharmaceutical and pharmacological research. It serves as an important source of information for researchers concerned with drug research and all those who need to keep abreast of the many recent developments in the quest for new and better medicines.
Progress in Drug Research is a prestigious book series which provides extensive expert-written reviews on a wide spectrum of highly topical areas in current pharmaceutical and pharmacological research. It serves as an important source of information for researchers concerned with drug research and all those who need to keep abreast of the many recent developments in the quest for new and better medicines.
Faculties, publications and doctoral theses in departments or divisions of chemistry, chemical engineering, biochemistry and pharmaceutical and/or medicinal chemistry at universities in the United States and Canada.
None